A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Sponsor: Bristol-Myers Squibb
Listed as NCT04877288, this PHASE3 trial focuses on Renal Allograft Recipients and remains actively recruiting participants. Sponsored by Bristol-Myers Squibb, it has been updated 24 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
24 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE3
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
▶ Show 19 earlier versions
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Jul 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Feb 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE3
-
Feb 2024 — Apr 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE3
-
Apr 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Mar 2023 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Apr 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
ABB, Argentina , Amsterdam, Netherlands , Atlanta, United States , Baltimore, United States , Barcelona, Spain , Birmingham, United States , Bordeaux, France , Boston, United States , Bron, France , Buenos Aires, Argentina and 27 more locations